Article: MicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleMicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma
AuthorsBurchard, J1 4
Zhang, C2 4
Liu, AM3 7
Poon, RTP3
Lee, NPY3
Wong, KF3 7
Sham, PC3
Lam, BY6
Ferguson, MD2 4
Tokiwa, G4 5
Smith, R2 4
Leeson, B4
Beard, R4
Lamb, JR4 8
Lim, L1 4
Mao, M4 8
Dai, H2 4
Luk, JM3 7
Keywordshepatocellular carcinoma
microarray
miR-122
mitochondrial
survival
Issue Date2010
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/msb/index.html
CitationMolecular Systems Biology, 2010, v. 6 [How to Cite?]
DOI: http://dx.doi.org/10.1038/msb.2010.58
AbstractTumorigenesis involves multistep genetic alterations. To elucidate the microRNA (miRNA)-gene interaction network in carcinogenesis, we examined their genome-wide expression profiles in 96 pairs of tumor/non-tumor tissues from hepatocellular carcinoma (HCC). Comprehensive analysis of the coordinate expression of miRNAs and mRNAs reveals that miR-122 is under-expressed in HCC and that increased expression of miR-122 seed-matched genes leads to a loss of mitochondrial metabolic function. Furthermore, the miR-122 secondary targets, which decrease in expression, are good prognostic markers for HCC. Transcriptome profiling data from additional 180 HCC and 40 liver cirrhotic patients in the same cohort were used to confirm the anti-correlation of miR-122 primary and secondary target gene sets. The HCC findings can be recapitulated in mouse liver by silencing miR-122 with antagomir treatment followed by gene-expression microarray analysis. In vitro miR-122 data further provided a direct link between induction of miR-122-controlled genes and impairment of mitochondrial metabolism. In conclusion, miR-122 regulates mitochondrial metabolism and its loss may be detrimental to sustaining critical liver function and contribute to morbidity and mortality of liver cancer patients. © 2010 EMBO and Macmillan Publishers Limited.
ISSN1744-4292
2011 Impact Factor: 8.626
2011 SCImago Journal Rankings: 2.349
DOIhttp://dx.doi.org/10.1038/msb.2010.58
ISI Accession Number IDWOS:000284527700003
Funding AgencyGrant Number
Hong Kong University
NMRC Block Vote
National University of Singapore
Funding Information:

The work is partly supported by the small project fund of the Hong Kong University, NMRC Block Vote, and Start-up fund of the National University of Singapore to JML. We gratefully acknowledge Sheung-Tat Fan of Queen Mary Hospital for his expert clinical advice in HCC, Douglas Bassett and Alan Sachs of Merck and Co., Inc. for guidance and support of these studies, and C Frank Bennett and Christy Esau of Isis Pharmaceuticals, Inc. for provision of the anti-miR-122-treated mouse liver samples and for helpful discussions. In addition, we thank Ke Hao, Tao Xie, Steven Bartz, Walter Strapps, Lyndon Mitnaul, Luiz Miguel Camargo, Robert Phillips, Peter Shaw, Eric Schadt, Peter Linsley, and Carolyn Buser-Dopner of Merck and Co., Inc. for scientific input and helpful discussions.

PubMed Central IDPMC2950084
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorBurchard, J
dc.contributor.authorZhang, C
dc.contributor.authorLiu, AM
dc.contributor.authorPoon, RTP
dc.contributor.authorLee, NPY
dc.contributor.authorWong, KF
dc.contributor.authorSham, PC
dc.contributor.authorLam, BY
dc.contributor.authorFerguson, MD
dc.contributor.authorTokiwa, G
dc.contributor.authorSmith, R
dc.contributor.authorLeeson, B
dc.contributor.authorBeard, R
dc.contributor.authorLamb, JR
dc.contributor.authorLim, L
dc.contributor.authorMao, M
dc.contributor.authorDai, H
dc.contributor.authorLuk, JM
dc.date.accessioned2010-10-31T11:31:16Z
dc.date.available2010-10-31T11:31:16Z
dc.date.issued2010
dc.description.abstractTumorigenesis involves multistep genetic alterations. To elucidate the microRNA (miRNA)-gene interaction network in carcinogenesis, we examined their genome-wide expression profiles in 96 pairs of tumor/non-tumor tissues from hepatocellular carcinoma (HCC). Comprehensive analysis of the coordinate expression of miRNAs and mRNAs reveals that miR-122 is under-expressed in HCC and that increased expression of miR-122 seed-matched genes leads to a loss of mitochondrial metabolic function. Furthermore, the miR-122 secondary targets, which decrease in expression, are good prognostic markers for HCC. Transcriptome profiling data from additional 180 HCC and 40 liver cirrhotic patients in the same cohort were used to confirm the anti-correlation of miR-122 primary and secondary target gene sets. The HCC findings can be recapitulated in mouse liver by silencing miR-122 with antagomir treatment followed by gene-expression microarray analysis. In vitro miR-122 data further provided a direct link between induction of miR-122-controlled genes and impairment of mitochondrial metabolism. In conclusion, miR-122 regulates mitochondrial metabolism and its loss may be detrimental to sustaining critical liver function and contribute to morbidity and mortality of liver cancer patients. © 2010 EMBO and Macmillan Publishers Limited.
dc.description.naturepublished_or_final_version
dc.identifier.citationMolecular Systems Biology, 2010, v. 6 [How to Cite?]
DOI: http://dx.doi.org/10.1038/msb.2010.58
dc.identifier.citeulike7745353
dc.identifier.doihttp://dx.doi.org/10.1038/msb.2010.58
dc.identifier.epage402
dc.identifier.hkuros182520
dc.identifier.isiWOS:000284527700003
Funding AgencyGrant Number
Hong Kong University
NMRC Block Vote
National University of Singapore
Funding Information:

The work is partly supported by the small project fund of the Hong Kong University, NMRC Block Vote, and Start-up fund of the National University of Singapore to JML. We gratefully acknowledge Sheung-Tat Fan of Queen Mary Hospital for his expert clinical advice in HCC, Douglas Bassett and Alan Sachs of Merck and Co., Inc. for guidance and support of these studies, and C Frank Bennett and Christy Esau of Isis Pharmaceuticals, Inc. for provision of the anti-miR-122-treated mouse liver samples and for helpful discussions. In addition, we thank Ke Hao, Tao Xie, Steven Bartz, Walter Strapps, Lyndon Mitnaul, Luiz Miguel Camargo, Robert Phillips, Peter Shaw, Eric Schadt, Peter Linsley, and Carolyn Buser-Dopner of Merck and Co., Inc. for scientific input and helpful discussions.

dc.identifier.issn1744-4292
2011 Impact Factor: 8.626
2011 SCImago Journal Rankings: 2.349
dc.identifier.openurl
dc.identifier.pmcidPMC2950084
dc.identifier.pmid20739924
dc.identifier.scopuseid_2-s2.0-77956249298
dc.identifier.spage402
dc.identifier.urihttp://hdl.handle.net/10722/125435
dc.identifier.volume6
dc.languageeng
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/msb/index.html
dc.publisher.placeUnited Kingdom
dc.relation.ispartofMolecular Systems Biology
dc.relation.referencesReferences in Scopus
dc.subject.meshCarcinoma, Hepatocellular - genetics
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshGene Regulatory Networks - genetics
dc.subject.meshLiver Neoplasms - genetics
dc.subject.meshMicroRNAs - genetics - metabolism
dc.subjecthepatocellular carcinoma
dc.subjectmicroarray
dc.subjectmiR-122
dc.subjectmitochondrial
dc.subjectsurvival
dc.titleMicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma
dc.typeArticle
Author Affiliations
  1. Sirna Therapeutics Inc.
  2. Merck Research Laboratories
  3. The University of Hong Kong
  4. Rosetta Inpharmatics LLC
  5. Merck & Co.
  6. University of Cambridge
  7. National University of Singapore
  8. Pfizer